Literature DB >> 19319146

Transforming growth factor-beta signaling alters substrate permeability and tight junction protein expression at the blood-brain barrier during inflammatory pain.

Patrick T Ronaldson1, Kristin M Demarco, Lucy Sanchez-Covarrubias, Christine M Solinsky, Thomas P Davis.   

Abstract

Our laboratory has shown that peripheral inflammatory pain induced by lambda-carrageenan (CIP) can increase blood-brain barrier (BBB) permeability and alter tight junction (TJ) protein expression leading to changes in BBB functional integrity. However, the intracellular signaling mechanisms involved in this pathophysiologic response have not been elucidated. Transforming growth factor (TGF)-beta signaling pathways are known to regulate vascular integrity and permeability. Therefore, we examined the function of TGF-beta signaling at the BBB in rats subjected to CIP. During CIP, serum TGF-beta1 and protein expression of the TGF-beta receptor activin receptor-like kinase-5 (ALK5) were reduced. Brain permeability to (14)C-sucrose was increased and expression of TJ proteins (i.e., claudin-5, occludin, zonula occluden (ZO-1)) were also altered after 3 h CIP. Pharmacological inhibition of ALK5 with the selective inhibitor SB431542 further enhanced brain uptake of (14)C-sucrose, increased TJ protein expression (i.e., claudin-3, claudin-5, occludin, ZO-1), and decreased nuclear expression of TGF-beta/ALK5 signaling molecules (i.e., Smad2, Smad3), which suggests a role for TGF-beta/ALK5 signaling in the regulation of BBB integrity. Interestingly, administration of exogenous TGF-beta1 before CIP activated the TGF-beta/ALK5 pathway and reduced BBB permeability to (14)C-sucrose. Taken together, our data show that TGF-beta/ALK5 signaling is, in part, involved in the regulation of BBB functional integrity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19319146      PMCID: PMC3910515          DOI: 10.1038/jcbfm.2009.32

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  41 in total

1.  Quantification of early blood-brain barrier disruption by in situ brain perfusion technique.

Authors:  A K Bhattacharjee; T Nagashima; T Kondoh; N Tamaki
Journal:  Brain Res Brain Res Protoc       Date:  2001-10

2.  Protein kinase C regulates the phosphorylation and cellular localization of occludin.

Authors:  A Y Andreeva; E Krause; E C Müller; I E Blasig; D I Utepbergenov
Journal:  J Biol Chem       Date:  2001-08-13       Impact factor: 5.157

3.  Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors.

Authors:  Marie-José Goumans; Gudrun Valdimarsdottir; Susumu Itoh; Alexander Rosendahl; Paschalis Sideras; Peter ten Dijke
Journal:  EMBO J       Date:  2002-04-02       Impact factor: 11.598

4.  Claudin 5 is transiently expressed during the development of the retinal pigment epithelium.

Authors:  S Kojima; C Rahner; S Peng; L J Rizzolo
Journal:  J Membr Biol       Date:  2002-03-15       Impact factor: 1.843

5.  Inflammatory pain alters blood-brain barrier permeability and tight junctional protein expression.

Authors:  J D Huber; K A Witt; S Hom; R D Egleton; K S Mark; T P Davis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-03       Impact factor: 4.733

6.  Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice.

Authors:  J Larsson; M J Goumans; L J Sjöstrand; M A van Rooijen; D Ward; P Levéen; X Xu; P ten Dijke; C L Mummery; S Karlsson
Journal:  EMBO J       Date:  2001-04-02       Impact factor: 11.598

7.  Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line.

Authors:  Jason A Zastre; Gary N Y Chan; Patrick T Ronaldson; Manisha Ramaswamy; Pierre O Couraud; Ignacio A Romero; Babette Weksler; Moise Bendayan; Reina Bendayan
Journal:  J Neurosci Res       Date:  2009-03       Impact factor: 4.164

8.  Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542.

Authors:  N J Laping; E Grygielko; A Mathur; S Butter; J Bomberger; C Tweed; W Martin; J Fornwald; R Lehr; J Harling; L Gaster; J F Callahan; B A Olson
Journal:  Mol Pharmacol       Date:  2002-07       Impact factor: 4.436

9.  SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.

Authors:  Gareth J Inman; Francisco J Nicolás; James F Callahan; John D Harling; Laramie M Gaster; Alastair D Reith; Nicholas J Laping; Caroline S Hill
Journal:  Mol Pharmacol       Date:  2002-07       Impact factor: 4.436

10.  Direct binding of three tight junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the COOH termini of claudins.

Authors:  M Itoh; M Furuse; K Morita; K Kubota; M Saitou; S Tsukita
Journal:  J Cell Biol       Date:  1999-12-13       Impact factor: 10.539

View more
  70 in total

1.  Effects of hepatic ischemia-reperfusion injury on the blood-brain barrier permeability to [14C] and [13C]sucrose.

Authors:  Mohammad K Miah; Ulrich Bickel; Reza Mehvar
Journal:  Metab Brain Dis       Date:  2017-08-04       Impact factor: 3.584

2.  Free insulin-like growth factor binding protein-3 (IGFBP-3) reduces retinal vascular permeability in association with a reduction of acid sphingomyelinase (ASMase).

Authors:  Jennifer L Kielczewski; Sergio Li Calzi; Lynn C Shaw; Jun Cai; Xiaoping Qi; Qing Ruan; Lin Wu; Li Liu; Ping Hu; Tailoi Chan-Ling; Robert N Mames; Sue Firth; Robert C Baxter; Patric Turowski; Julia V Busik; Michael E Boulton; Maria B Grant
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-10-21       Impact factor: 4.799

Review 3.  Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Ther Deliv       Date:  2011-08

Review 4.  Targeting the neurovascular unit for treatment of neurological disorders.

Authors:  Reyna L Vangilder; Charles L Rosen; Taura L Barr; Jason D Huber
Journal:  Pharmacol Ther       Date:  2010-12-21       Impact factor: 12.310

Review 5.  Cytokine signaling modulates blood-brain barrier function.

Authors:  Weihong Pan; Kirsten P Stone; Hung Hsuchou; Vamshi K Manda; Yan Zhang; Abba J Kastin
Journal:  Curr Pharm Des       Date:  2011-11       Impact factor: 3.116

Review 6.  Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 7.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

8.  PDGFR-β restores blood-brain barrier functions in a mouse model of focal cerebral ischemia.

Authors:  Jie Shen; Guihua Xu; Runxiu Zhu; Jun Yuan; Yoko Ishii; Takeru Hamashima; Takako Matsushima; Seiji Yamamoto; Yusuke Takatsuru; Junichi Nabekura; Masakiyo Sasahara
Journal:  J Cereb Blood Flow Metab       Date:  2018-04-09       Impact factor: 6.200

9.  CD8 T cell-initiated vascular endothelial growth factor expression promotes central nervous system vascular permeability under neuroinflammatory conditions.

Authors:  Georgette L Suidan; Jonathan W Dickerson; Yi Chen; Jeremiah R McDole; Pulak Tripathi; Istvan Pirko; Kim B Seroogy; Aaron J Johnson
Journal:  J Immunol       Date:  2009-12-11       Impact factor: 5.422

10.  Interleukin-25 expressed by brain capillary endothelial cells maintains blood-brain barrier function in a protein kinase Cepsilon-dependent manner.

Authors:  Yoshifumi Sonobe; Hideyuki Takeuchi; Kunio Kataoka; Hua Li; Shijie Jin; Maya Mimuro; Yoshio Hashizume; Yasuteru Sano; Takashi Kanda; Tetsuya Mizuno; Akio Suzumura
Journal:  J Biol Chem       Date:  2009-09-23       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.